Black Diamond Therapeutics (NASDAQ:BDTX) Price Target Raised to $12.00

Black Diamond Therapeutics (NASDAQ:BDTX) had its target price boosted by HC Wainwright from $11.00 to $12.00 in a report published on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Black Diamond Therapeutics’ Q1 2025 earnings at ($0.32) EPS, Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.34) EPS and FY2025 earnings at ($1.32) EPS.

A number of other equities analysts have also commented on the stock. Wedbush restated an “outperform” rating and issued a $11.00 price target (down from $16.00) on shares of Black Diamond Therapeutics in a research report on Friday, March 7th. Stifel Nicolaus reduced their target price on shares of Black Diamond Therapeutics from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $14.60.

Black Diamond Therapeutics Stock Up 9.3 %

NASDAQ:BDTX opened at $1.88 on Tuesday. The firm has a market cap of $106.52 million, a PE ratio of -1.41 and a beta of 2.52. Black Diamond Therapeutics has a 12 month low of $1.59 and a 12 month high of $7.66. The company’s 50-day moving average price is $2.16 and its two-hundred day moving average price is $2.92.

Black Diamond Therapeutics (NASDAQ:BDTX) last released its quarterly earnings results on Thursday, March 6th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03. On average, research analysts expect that Black Diamond Therapeutics will post -1.3 EPS for the current fiscal year.

Insider Transactions at Black Diamond Therapeutics

In related news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of the business’s stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $2.07, for a total transaction of $11,973,484.44. Following the completion of the sale, the insider now directly owns 2,733,547 shares of the company’s stock, valued at $5,658,442.29. The trade was a 67.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 8.87% of the stock is owned by company insiders.

Institutional Investors Weigh In On Black Diamond Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of BDTX. D. E. Shaw & Co. Inc. bought a new stake in shares of Black Diamond Therapeutics during the fourth quarter worth approximately $37,000. Intech Investment Management LLC raised its stake in shares of Black Diamond Therapeutics by 49.1% during the fourth quarter. Intech Investment Management LLC now owns 19,247 shares of the company’s stock worth $41,000 after buying an additional 6,340 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Black Diamond Therapeutics by 429.6% during the fourth quarter. JPMorgan Chase & Co. now owns 18,929 shares of the company’s stock worth $41,000 after buying an additional 15,355 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Black Diamond Therapeutics during the fourth quarter worth approximately $42,000. Finally, Wells Fargo & Company MN raised its stake in shares of Black Diamond Therapeutics by 41.8% during the fourth quarter. Wells Fargo & Company MN now owns 20,119 shares of the company’s stock worth $43,000 after buying an additional 5,932 shares during the last quarter. 95.47% of the stock is owned by institutional investors.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.